Biogen Idec Inc (BIIB) 263.94 $BIIB
3 Stocks That Are Ridiculously Cheap Right Now
Matthew Frankel, Sean Williams, and Brian Feroldi, The Motley Fool - Motley Fool - Sat Mar 05, 1:43PM CST
Source: www.401kcalculator.org The stock market's performance so far in 2016 hasn't exactly been stellar, with the S&P 500 still down 3% for the year, even after a pretty strong rebound. While it's never fun to watch the value of your...
BIIB: 263.94 (-4.70), HCP: 31.50 (+0.12), BKD: 15.73 (+0.59), BAC: 13.54 (+0.04), UBS: 16.51 (-0.01), IONS: 39.81 (+1.40)
What Does Trump's Healthcare Plan Mean for Investors?
Arpita Dutt - Zacks Investment Research - Fri Mar 04, 10:57AM CST
The pharma industry has always stood strongly against attempts to legalize drug re-importation.
BIIB: 263.94 (-4.70), VRX: 61.31 (-3.58), VRTX: 88.36 (-1.09), GILD: 87.21 (-0.62), AMGN: 145.98 (+0.14), REGN: 403.82 (+1.88)
Biogen and Other Biotech Stocks Are About to Rally, These 3 Charts Show
at The Street - Sun Feb 21, 2:05PM CST
Biotech stocks have been hit hard since last summer, but comprehensive technical analysis shows they'll bounce soon. Here's how you can profit.
BIIB: 263.94 (-4.70), GILD: 87.21 (-0.62)
Is Big Pharma Evil?
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Sun Feb 21, 1:06PM CST
Big Pharma has been making a lot of unfortunate headlines lately, especially after Turing Pharmaceuticals' debacle surrounding pricing of Daraprim. Having once been a reasonably respected sector, recent studies have shown that in America, pharma is...
JNJ: 106.50 (-0.15), BIIB: 263.94 (-4.70), GILD: 87.21 (-0.62)
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2015 Update
John Vincent - at Seeking Alpha - Sun Feb 21, 6:17AM CST
SIRO: 109.97 (-0.13), MON: 85.89 (+0.95), EVHC: 23.25 (-0.30), PRU: 71.47 (-0.40), NKE: 61.26 (-0.21), KSU: 86.65 (+0.23), AMP: 90.46 (+0.92), LM: 32.42 (+0.57), RRC: 32.32 (+1.59), AET: 108.06 (-1.58), GOOG: 710.89 (-1.53), GPOR: 25.60 (+0.33), HOT: 70.55 (+0.48), HLT: 21.89 (+0.30), LYB: 82.00 (+2.10), COG: 21.47 (-0.70), WCG: 93.24 (-0.36), MA: 90.05 (+0.31), MNK: 62.15 (-1.44), WUBA: 55.70 (+1.45), WLL: 7.09 (+0.78), VRTX: 88.36 (-1.09), MCK: 162.77 (+0.07), ETN: 57.95 (+0.12), SEE: 45.68 (-0.84), AKRX: 25.08 (-0.80), PFE: 29.71 (-0.18), HAL: 34.88 (+0.71), LNG: 38.04 (+0.99), ETE: 8.33 (+0.43), TXT: 33.00 (-0.64), ALL: 65.38 (+0.07), PCLN: 1,297.71 (-5.33), QUNR: 36.95 (+0.73), WBA: 79.45 (-0.47), PXD: 128.80 (+0.53), MCD: 117.18 (+0.49), TEVA: 55.62 (+0.02), DOV: 63.20 (+0.75), AIG: 52.30 (+0.03), XRAY: 60.16 (-0.46), FDC: 13.59 (+0.80), CCI: 87.25 (-0.64), BIIB: 263.94 (-4.70), VRX: 61.31 (-3.58), CPN: 14.14 (+0.26), C: 42.83 (unch), ILMN: 156.14 (-1.31), CB: 117.18 (-0.66), MMC: 58.01 (+0.26), HUM: 183.25 (+0.03), AGN: 288.67 (-0.95), ANTM: 132.35 (-0.62), ECA: 5.47 (+0.54), PRQR: 4.54 (+0.14), EBAY: 24.41 (+0.47), SHPG: 160.39 (+0.20), CMG: 529.00 (+4.71), GOOGL: 730.22 (-1.37), CTRP: 40.02 (+0.78), SWN: 7.83 (+0.49), BK: 38.09 (+0.40), APD: 134.79 (-0.09), BHI: 46.20 (-0.35), APC: 45.26 (+2.28), AMZN: 575.14 (-2.35), ENDP: 42.44 (-0.73), MAR: 68.98 (+0.30), NFLX: 101.58 (+3.65), DVA: 70.51 (+0.43), KITE: 54.44 (+2.70), MHK: 186.82 (-0.07), TDG: 222.68 (+3.05), LH: 112.17 (+0.25), CP: 125.26 (+3.28), AFL: 61.03 (+0.05), AVGO: 146.06 (+8.73), BABA: 72.22 (+1.20)
Stock Market News for February 19, 2016
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 9:10AM CST
Benchmarks closed in the red after three consecutive sessions of gains following volatile oil price movement and weak outlook for the next quarter and fiscal year from Wal-Mart
BIIB: 263.94 (-4.70), WMT: 66.78 (+0.64), XOM: 82.29 (-0.11), AMGN: 145.98 (+0.14), SLB: 74.83 (-0.02), CELG: 102.51 (-0.22), PXD: 128.80 (+0.53), GS: 156.84 (+1.51), JPM: 60.05 (+0.09), GILD: 87.21 (-0.62), IBM: 137.80 (unch), EOG: 71.41 (+2.16), OXY: 69.72 (-0.77), CVX: 87.93 (+0.40), AAPL: 103.01 (+1.51)
Perrigo Lags on Q4 Earnings and Revenues, Updates View
Zacks Equity Research - Zacks Investment Research - Thu Feb 18, 10:13AM CST
Perrigo Company (PRGO) reported fourth-quarter 2015 earnings of $1.80 per share.
BIIB: 263.94 (-4.70), PRGO: 126.61 (+0.19), ANIK: 45.07 (-0.43), CELG: 102.51 (-0.22)
Covered Call Alerts For Chesapeake Energy, Microsoft, Gilead Sciences, Biogen and JetBlue Released By InvestorsObserver
PR Newswire - Wed Feb 10, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for CHK, MSFT, GILD, BIIB and JBLU.
BIIB: 263.94 (-4.70), GILD: 87.21 (-0.62), CHK: 5.08 (+0.81), JBLU: 21.98 (-0.27), MSFT: 52.03 (-0.32)
The Agony of High Returns
Morgan Housel, The Motley Fool - Motley Fool - Tue Feb 09, 1:28PM CST
Monster Beverage (NASDAQ: MNST) was the best-performing stock from 1995 to 2015. It increased 105,000%, turning $10,000 into more than $10 million. But this isn't a retrospective about how you should wish you owned Monster stock. It's almost the...
MNST: 128.89 (+0.42), BIIB: 263.94 (-4.70), GILD: 87.21 (-0.62)
Biotech ETFs Slide as Stocks Report Mixed Q4 Results
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 12:48PM CST
Thanks to mixed results, the biotech sector has failed to gain investor confidence so far in the fourth quarter.
PBE: 38.64 (-0.12), BIIB: 263.94 (-4.70), GILD: 87.21 (-0.62), FBT: 88.37 (+0.55), ALXN: 144.46 (-1.39), BBH: 103.52 (-0.23), IBB: 263.13 (-1.11), AMGN: 145.98 (+0.14), CELG: 102.51 (-0.22)
Former Leaders Show Up On New Low List; D.R. Horton Sinks Again
at Investor's Business Daily - Mon Feb 08, 5:37PM CST
The market is sinking further into a correction and the number of stocks on the new low list swamps the number on the new high list. Among the casualties that made 52-week lows were some former leaders that not long ago looked like they were breaking...
DHI: 28.40 (-0.23), BIIB: 263.94 (-4.70), EA: 64.43 (-0.37), JAZZ: 123.76 (-1.70), TSN: 64.96 (-1.06)
Biogen Idec Falls 4.96% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Feb 08, 5:34PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $248.16 to a high of $260.45. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $258.46 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 263.94 (-4.70)
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 4.96%
Comtex SmarTrend(R) - Mon Feb 08, 5:33PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $248.16 to a high of $260.45. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $258.46 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 263.94 (-4.70)
AGTC Announces Financial Results for the Quarter Ended December 31, 2015
GlobeNewswire - Mon Feb 08, 3:01PM CST
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, with a primary focus on ophthalmology, today announced financial results for the quarter ended December 31, 2015. The company also announced that Biogen (NASDAQ:BIIB) has selected adrenoleukodystrophy (ALD) as the first publicly announced of the three discovery programs under its collaboration with AGTC.
AGTC: 14.13 (-0.33), BIIB: 263.94 (-4.70)
Biogen Inc. Takes Aim at Johnson & Johnson
Todd Campbell, The Motley Fool - Motley Fool - Sun Feb 07, 6:20AM CST
Source: Biogen. The launch of a biosimilar to Johnson & Johnson 's top-selling Remicade this year is a key goal of a joint venture between Biogen Inc. and South Korea-based Samsung. And if that happens, then it could mean billions of...
JNJ: 106.50 (-0.15), BIIB: 263.94 (-4.70), AMGN: 145.98 (+0.14), NVS: 72.20 (-0.75)
LinkedIn Downgraded; Biotechs Initiated; Tableau PT Cut
at Investor's Business Daily - Fri Feb 05, 3:45PM CST
LinkedIn (LNKD) was downgraded Friday after reporting weak guidance Thursday. Celgene (CELG) and other biotechs were started with a market perform rating. LinkedIn was downgraded to sector perform from outperform by RBC Capital Markets. The...
AMZN: 575.14 (-2.35), BIIB: 263.94 (-4.70), LNKD: 119.35 (+2.32), COP: 41.12 (+2.56), AMGN: 145.98 (+0.14), DATA: 42.75 (-0.37), CELG: 102.51 (-0.22)
Biogen (BIIB) Stock Gets ‘Market Perform’ Rating at Leerink
at The Street - Fri Feb 05, 1:52PM CST
Leerink reinstated coverage of Biogen (BIIB) stock with a ‘market perform’ rating and $335 price target.
BIIB: 263.94 (-4.70)
Technical Recap on Biotechnology Equities -- Biogen, Medivation, Grifols, and Agios Pharma
ACCESSWIRE - Fri Feb 05, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / February 05, 2016 / Park Lane Advisor has initiated coverage on the following equities: Biogen Inc. (NASDAQ: BIIB), Medivation Inc. (NASDAQ: MDVN), Grifols S.A. (NASDAQ: GRFS), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Free note on Biogen can be accessed at http://www.parklaneadvisor.com/ On Thursday, February 04, 2016, the NASDAQ Composite ended at 4,509.56, up 0.12%, the Dow Jones Industrial Average advanced 0.49%, to finish the day at 16,416.58, and the S&P 500 closed at 1,915.45, up 0.15%. The gains were broad based as five out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
MDVN: 40.44 (+2.24), BIIB: 263.94 (-4.70), AGIO: 44.32 (+1.36), GRFS: 15.22 (-0.27)
Watch for Biogen Idec to Potentially Pullback After Gaining 1.05% Yesterday
Comtex SmarTrend(R) - Thu Feb 04, 4:27PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $269.11 to a high of $279.38. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $275.83 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 263.94 (-4.70)
3 Stocks That Are Ridiculously Cheap Right Now
Matthew Frankel, Sean Williams, and Brian Feroldi, The Motley Fool - Motley Fool - Sat Mar 05, 1:43PM CST
Source: www.401kcalculator.org The stock market's performance so far in 2016 hasn't exactly been stellar, with the S&P 500 still down 3% for the year, even after a pretty strong rebound. While it's never fun to watch the value of your...
BIIB: 263.94 (-4.70), HCP: 31.50 (+0.12), BKD: 15.73 (+0.59), BAC: 13.54 (+0.04), UBS: 16.51 (-0.01), IONS: 39.81 (+1.40)
What Does Trump's Healthcare Plan Mean for Investors?
Arpita Dutt - Zacks Investment Research - Fri Mar 04, 10:57AM CST
The pharma industry has always stood strongly against attempts to legalize drug re-importation.
BIIB: 263.94 (-4.70), VRX: 61.31 (-3.58), VRTX: 88.36 (-1.09), GILD: 87.21 (-0.62), AMGN: 145.98 (+0.14), REGN: 403.82 (+1.88)
Biogen and Other Biotech Stocks Are About to Rally, These 3 Charts Show
at The Street - Sun Feb 21, 2:05PM CST
Biotech stocks have been hit hard since last summer, but comprehensive technical analysis shows they'll bounce soon. Here's how you can profit.
BIIB: 263.94 (-4.70), GILD: 87.21 (-0.62)
Is Big Pharma Evil?
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Sun Feb 21, 1:06PM CST
Big Pharma has been making a lot of unfortunate headlines lately, especially after Turing Pharmaceuticals' debacle surrounding pricing of Daraprim. Having once been a reasonably respected sector, recent studies have shown that in America, pharma is...
JNJ: 106.50 (-0.15), BIIB: 263.94 (-4.70), GILD: 87.21 (-0.62)
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2015 Update
John Vincent - at Seeking Alpha - Sun Feb 21, 6:17AM CST
SIRO: 109.97 (-0.13), MON: 85.89 (+0.95), EVHC: 23.25 (-0.30), PRU: 71.47 (-0.40), NKE: 61.26 (-0.21), KSU: 86.65 (+0.23), AMP: 90.46 (+0.92), LM: 32.42 (+0.57), RRC: 32.32 (+1.59), AET: 108.06 (-1.58), GOOG: 710.89 (-1.53), GPOR: 25.60 (+0.33), HOT: 70.55 (+0.48), HLT: 21.89 (+0.30), LYB: 82.00 (+2.10), COG: 21.47 (-0.70), WCG: 93.24 (-0.36), MA: 90.05 (+0.31), MNK: 62.15 (-1.44), WUBA: 55.70 (+1.45), WLL: 7.09 (+0.78), VRTX: 88.36 (-1.09), MCK: 162.77 (+0.07), ETN: 57.95 (+0.12), SEE: 45.68 (-0.84), AKRX: 25.08 (-0.80), PFE: 29.71 (-0.18), HAL: 34.88 (+0.71), LNG: 38.04 (+0.99), ETE: 8.33 (+0.43), TXT: 33.00 (-0.64), ALL: 65.38 (+0.07), PCLN: 1,297.71 (-5.33), QUNR: 36.95 (+0.73), WBA: 79.45 (-0.47), PXD: 128.80 (+0.53), MCD: 117.18 (+0.49), TEVA: 55.62 (+0.02), DOV: 63.20 (+0.75), AIG: 52.30 (+0.03), XRAY: 60.16 (-0.46), FDC: 13.59 (+0.80), CCI: 87.25 (-0.64), BIIB: 263.94 (-4.70), VRX: 61.31 (-3.58), CPN: 14.14 (+0.26), C: 42.83 (unch), ILMN: 156.14 (-1.31), CB: 117.18 (-0.66), MMC: 58.01 (+0.26), HUM: 183.25 (+0.03), AGN: 288.67 (-0.95), ANTM: 132.35 (-0.62), ECA: 5.47 (+0.54), PRQR: 4.54 (+0.14), EBAY: 24.41 (+0.47), SHPG: 160.39 (+0.20), CMG: 529.00 (+4.71), GOOGL: 730.22 (-1.37), CTRP: 40.02 (+0.78), SWN: 7.83 (+0.49), BK: 38.09 (+0.40), APD: 134.79 (-0.09), BHI: 46.20 (-0.35), APC: 45.26 (+2.28), AMZN: 575.14 (-2.35), ENDP: 42.44 (-0.73), MAR: 68.98 (+0.30), NFLX: 101.58 (+3.65), DVA: 70.51 (+0.43), KITE: 54.44 (+2.70), MHK: 186.82 (-0.07), TDG: 222.68 (+3.05), LH: 112.17 (+0.25), CP: 125.26 (+3.28), AFL: 61.03 (+0.05), AVGO: 146.06 (+8.73), BABA: 72.22 (+1.20)
Stock Market News for February 19, 2016
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 9:10AM CST
Benchmarks closed in the red after three consecutive sessions of gains following volatile oil price movement and weak outlook for the next quarter and fiscal year from Wal-Mart
BIIB: 263.94 (-4.70), WMT: 66.78 (+0.64), XOM: 82.29 (-0.11), AMGN: 145.98 (+0.14), SLB: 74.83 (-0.02), CELG: 102.51 (-0.22), PXD: 128.80 (+0.53), GS: 156.84 (+1.51), JPM: 60.05 (+0.09), GILD: 87.21 (-0.62), IBM: 137.80 (unch), EOG: 71.41 (+2.16), OXY: 69.72 (-0.77), CVX: 87.93 (+0.40), AAPL: 103.01 (+1.51)
Perrigo Lags on Q4 Earnings and Revenues, Updates View
Zacks Equity Research - Zacks Investment Research - Thu Feb 18, 10:13AM CST
Perrigo Company (PRGO) reported fourth-quarter 2015 earnings of $1.80 per share.
BIIB: 263.94 (-4.70), PRGO: 126.61 (+0.19), ANIK: 45.07 (-0.43), CELG: 102.51 (-0.22)
Covered Call Alerts For Chesapeake Energy, Microsoft, Gilead Sciences, Biogen and JetBlue Released By InvestorsObserver
PR Newswire - Wed Feb 10, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for CHK, MSFT, GILD, BIIB and JBLU.
BIIB: 263.94 (-4.70), GILD: 87.21 (-0.62), CHK: 5.08 (+0.81), JBLU: 21.98 (-0.27), MSFT: 52.03 (-0.32)
The Agony of High Returns
Morgan Housel, The Motley Fool - Motley Fool - Tue Feb 09, 1:28PM CST
Monster Beverage (NASDAQ: MNST) was the best-performing stock from 1995 to 2015. It increased 105,000%, turning $10,000 into more than $10 million. But this isn't a retrospective about how you should wish you owned Monster stock. It's almost the...
MNST: 128.89 (+0.42), BIIB: 263.94 (-4.70), GILD: 87.21 (-0.62)
Biotech ETFs Slide as Stocks Report Mixed Q4 Results
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 12:48PM CST
Thanks to mixed results, the biotech sector has failed to gain investor confidence so far in the fourth quarter.
PBE: 38.64 (-0.12), BIIB: 263.94 (-4.70), GILD: 87.21 (-0.62), FBT: 88.37 (+0.55), ALXN: 144.46 (-1.39), BBH: 103.52 (-0.23), IBB: 263.13 (-1.11), AMGN: 145.98 (+0.14), CELG: 102.51 (-0.22)
Former Leaders Show Up On New Low List; D.R. Horton Sinks Again
at Investor's Business Daily - Mon Feb 08, 5:37PM CST
The market is sinking further into a correction and the number of stocks on the new low list swamps the number on the new high list. Among the casualties that made 52-week lows were some former leaders that not long ago looked like they were breaking...
DHI: 28.40 (-0.23), BIIB: 263.94 (-4.70), EA: 64.43 (-0.37), JAZZ: 123.76 (-1.70), TSN: 64.96 (-1.06)
Biogen Idec Falls 4.96% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Feb 08, 5:34PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $248.16 to a high of $260.45. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $258.46 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 263.94 (-4.70)
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 4.96%
Comtex SmarTrend(R) - Mon Feb 08, 5:33PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $248.16 to a high of $260.45. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $258.46 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 263.94 (-4.70)
AGTC Announces Financial Results for the Quarter Ended December 31, 2015
GlobeNewswire - Mon Feb 08, 3:01PM CST
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, with a primary focus on ophthalmology, today announced financial results for the quarter ended December 31, 2015. The company also announced that Biogen (NASDAQ:BIIB) has selected adrenoleukodystrophy (ALD) as the first publicly announced of the three discovery programs under its collaboration with AGTC.
AGTC: 14.13 (-0.33), BIIB: 263.94 (-4.70)
Biogen Inc. Takes Aim at Johnson & Johnson
Todd Campbell, The Motley Fool - Motley Fool - Sun Feb 07, 6:20AM CST
Source: Biogen. The launch of a biosimilar to Johnson & Johnson 's top-selling Remicade this year is a key goal of a joint venture between Biogen Inc. and South Korea-based Samsung. And if that happens, then it could mean billions of...
JNJ: 106.50 (-0.15), BIIB: 263.94 (-4.70), AMGN: 145.98 (+0.14), NVS: 72.20 (-0.75)
LinkedIn Downgraded; Biotechs Initiated; Tableau PT Cut
at Investor's Business Daily - Fri Feb 05, 3:45PM CST
LinkedIn (LNKD) was downgraded Friday after reporting weak guidance Thursday. Celgene (CELG) and other biotechs were started with a market perform rating. LinkedIn was downgraded to sector perform from outperform by RBC Capital Markets. The...
AMZN: 575.14 (-2.35), BIIB: 263.94 (-4.70), LNKD: 119.35 (+2.32), COP: 41.12 (+2.56), AMGN: 145.98 (+0.14), DATA: 42.75 (-0.37), CELG: 102.51 (-0.22)
Biogen (BIIB) Stock Gets ‘Market Perform’ Rating at Leerink
at The Street - Fri Feb 05, 1:52PM CST
Leerink reinstated coverage of Biogen (BIIB) stock with a ‘market perform’ rating and $335 price target.
BIIB: 263.94 (-4.70)
Technical Recap on Biotechnology Equities -- Biogen, Medivation, Grifols, and Agios Pharma
ACCESSWIRE - Fri Feb 05, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / February 05, 2016 / Park Lane Advisor has initiated coverage on the following equities: Biogen Inc. (NASDAQ: BIIB), Medivation Inc. (NASDAQ: MDVN), Grifols S.A. (NASDAQ: GRFS), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Free note on Biogen can be accessed at http://www.parklaneadvisor.com/ On Thursday, February 04, 2016, the NASDAQ Composite ended at 4,509.56, up 0.12%, the Dow Jones Industrial Average advanced 0.49%, to finish the day at 16,416.58, and the S&P 500 closed at 1,915.45, up 0.15%. The gains were broad based as five out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
MDVN: 40.44 (+2.24), BIIB: 263.94 (-4.70), AGIO: 44.32 (+1.36), GRFS: 15.22 (-0.27)
Watch for Biogen Idec to Potentially Pullback After Gaining 1.05% Yesterday
Comtex SmarTrend(R) - Thu Feb 04, 4:27PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $269.11 to a high of $279.38. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $275.83 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 263.94 (-4.70)
